These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37772996)

  • 1. Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer.
    Brasky TM; Newton AM; Conroy S; Adib A; Adley NC; Strassels SA; Hays JL; Cooper ZD; Wagener TL; Stevens E; Plascak JJ; Krok-Schoen JL
    Cancer Res Commun; 2023 Sep; 3(9):1917-1926. PubMed ID: 37772996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
    PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Health Care Providers Attitudes and Beliefs Regarding Medical Marijuana and Cannabidiol in the Management of Pain and Other Symptoms in Cancer Patients.
    Tanco K; Lopez G; Koyyalagunta L; Fellman B; Halm J; Ignatius J; Bruera E
    J Palliat Med; 2023 Apr; 26(4):539-543. PubMed ID: 36576904
    [No Abstract]   [Full Text] [Related]  

  • 4. Sex differences exist in the perceived relief of cancer symptoms with medical cannabis: results from the Quebec Cannabis Registry.
    Kasvis P; Canac-Marquis M; Aprikian S; Vigano M; Vigano A
    Support Care Cancer; 2022 Oct; 30(10):7863-7871. PubMed ID: 35723729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical Cannabis Use and Inflammatory Cytokines and Chemokines Among Adult Chronic Pain Patients.
    Ajrawat P; Yang Y; Wasilewski E; Leroux T; Ladha KS; Bhatia A; Singh M; Thaker S; Kapoor M; Furlan AD; Kotra LP; Clarke H
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):267-281. PubMed ID: 36342776
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of Dispensing and Utilization Patterns of Medical Cannabis Products in State Licensed Cannabis Dispensaries.
    Tanco K; Olson A; Fellman B; Jankowski M; Lai SY; Shete S; Harbison K; Scheid J; Bruera E
    J Palliat Med; 2023 Nov; 26(11):1482-1487. PubMed ID: 37285183
    [No Abstract]   [Full Text] [Related]  

  • 7. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.
    Boehnke KF; Gagnier JJ; Matallana L; Williams DA
    J Pain; 2021 May; 22(5):556-566. PubMed ID: 33400996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21.
    Sakal C; Lynskey M; Schlag AK; Nutt DJ
    Psychopharmacology (Berl); 2022 May; 239(5):1147-1155. PubMed ID: 33970291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association between Cannabis Product Characteristics and Symptom Relief.
    Stith SS; Vigil JM; Brockelman F; Keeling K; Hall B
    Sci Rep; 2019 Feb; 9(1):2712. PubMed ID: 30804402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.
    Boehnke KF; Gagnier JJ; Matallana L; Williams DA
    J Pain; 2021 Nov; 22(11):1418-1428. PubMed ID: 33992787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis for the treatment of ulcerative colitis.
    Kafil TS; Nguyen TM; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and Perceptions of Cannabidiol Products in Canada and in the United States.
    Goodman S; Wadsworth E; Schauer G; Hammond D
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):355-364. PubMed ID: 33998872
    [No Abstract]   [Full Text] [Related]  

  • 13. Cannabis-based medicines for chronic neuropathic pain in adults.
    Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
    Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
    BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).
    Good P; Haywood A; Gogna G; Martin J; Yates P; Greer R; Hardy J
    BMC Palliat Care; 2019 Dec; 18(1):110. PubMed ID: 31810437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
    Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
    Trials; 2024 May; 25(1):293. PubMed ID: 38693590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CannaCount: an improved metric for quantifying estimates of maximum possible cannabinoid exposure.
    Lambros AM; Sagar KA; Dahlgren MK; Kosereisoglu D; El-Abboud C; Smith RT; Gruber SA
    Sci Rep; 2023 Apr; 13(1):5869. PubMed ID: 37041309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of Tetrahydrocannabinol and Cannabidiol Levels Among Cannabis Consumers in the United States and Canada.
    Hammond D; Goodman S
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):345-354. PubMed ID: 33998866
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
    Legare CA; Raup-Konsavage WM; Vrana KE
    Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
    Mead A
    Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.